Welcome to Biomay

BIOMAY IS a Vienna based biotech company and the hub of an Austrian allergy research and development network. Scientists at the Medical University of Vienna and the University of Salzburg – the two most important network partners – have been pursuing RESEARCH FOR BETTER ALLERGY THERAPEUTICS AND DIAGNOSTICS for over 20 years. The network is playing a leading role in researching, developing and applying recombinant allergens and other innovative approaches to develop significantly improved allergy vaccines.

BIOMAY´s STRENGTH is its proprietary technology platform. Molecules from this platform have successfully passed phase II clinical trials for allergy vaccines. Biomay also offers a GMP contract manufacturing service for small lots, typically required for pre-clinical development and clinical trials. The production facility is certified for manufacturing of microbial-based biopharmaceuticals such as recombinant proteins and DNA-vaccines.

BIOMAY´s GOAL is to commercialize the extensive know-how and intellectual property created by the scientific network. Biomay is seeking partners with the capability to utilize the full strength of this platform, to develop and market a range of highly innovative allergy therapy products. The ultimate goal is to develop technologies suitable for prophylactic allergy vaccination.

NEWS